ArticleDiscover oncology2025
Comprehensive analysis of KLHL35 expression and its prognostic value in cancer: implications for colorectal cancer diagnosis and therapy.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study investigates the expression patterns and clinical relevance of KLHL35 (Kelch-Like Family Member 35) across various cancer types, with a focus on colorectal cancer. Comprehensive analysis of RNA sequencing data from The Cancer Genome Atlas (TCGA) and protein expression data from the Human Protein Atlas (HPA) revealed significant overexpression of KLHL35 in 13 tumor types, including colorectal cancer. Increased KLHL35 expression was associated with poor clinical outcomes, including overall survival (OS), progression-free interval (PFI), and disease-specific survival (DSS). Receiver operating characteristic (ROC) curve analysis suggested promising but exploratory diagnostic value for KLHL35, with area under the curve (AUC) values exceeding 0.9 in colorectal cancer. Functional enrichment analyses suggested potential associations between KLHL35 and cell cycle/apoptosis pathways, while immune infiltration correlations hinted at a possible role in immune microenvironment remodeling. In vitro assays confirmed KLHL35’s role in promoting cancer cell proliferation, invasion, and migration. These findings suggest that KLHL35 could serve as a valuable diagnostic and prognostic biomarker and a potential therapeutic target, particularly in colorectal cancer. While these findings nominate KLHL35 as a candidate for therapeutic targeting, further mechanistic studies are required to validate its function.”
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.